This week

EASD opens Monday in Milan, and Novo is bringing 44 abstracts — including the oral pill's first real-world test

The 62nd Annual Meeting of the European Association for the Study of Diabetes opens in Milan on Monday, September 28. Novo Nordisk published a preview of its conference program on September 16, 2026, announcing 44 abstracts covering semaglutide, CagriSema, and next-generation amylin treatments. The abstract most closely watched in the GLP-1 space: the OCTANE study, a real-world analysis of patients who switched from injectable semaglutide or tirzepatide to the oral Wegovy pill for weight management. It presents Wednesday, September 30. [BioSpace / Novo Nordisk preview](https://www.biospace.com/press-releases/novo-to-share-real-world-and-clinical-data-including-wegovy-pill-and-cardiometabolic-pipeline-progress-with-next-generation-amylin-treatments-at-easd-2026). The oral Wegovy tablet was FDA-approved in December 2025 and launched on January 5, 2026, surpassing 2 million prescriptions in its first four months — the fastest GLP-1 launch on record. The question the OCTANE data will start to answer is one no randomized controlled trial could: when patients who were already doing well on an injectable GLP-1 switched to the pill, did they hold their results? Real-world switchers are not the same as de novo trial patients, and their experience is what the commercial market now actually looks like. EASD Monday is when the real-world story begins.

The actual biology

a GLP-1 pill is technically much harder to make than a shot — here's the chemistry that solved it

Peptides get destroyed in the gut. Stomach acid and proteases are specifically designed to break down protein-based molecules before absorption — which is precisely why injectable semaglutide exists: modified with a fatty-acid chain, it binds albumin in the bloodstream and survives long enough to be active. Making an oral form required solving a different problem. The answer is SNAC — sodium salcaprozate, an absorption enhancer that forms a complex with semaglutide in the stomach, protecting it from enzymatic degradation and allowing absorption through the gastric mucosa before the drug reaches the small intestine. The pharmacological consequence is a dose differential: the oral tablet uses a much larger daily dose to achieve therapeutic blood levels, because oral bioavailability with SNAC is far lower than subcutaneous injection even with the complexing agent. The GLP-1 receptor biology is the same either way: activation suppresses appetite, slows gastric emptying, and drives glucose-dependent insulin release. [PubMed indexes over 11,000 semaglutide publications](https://pubmed.ncbi.nlm.nih.gov/?term=semaglutide), including pharmacokinetic studies documenting the SNAC mechanism across oral and injectable formulations. The molecule is the same. The delivery engineering is a different decade-long project.

The wellness claim

same drug, no needles — the behavioral ask the marketing doesn't lead with

The social conversation around oral Wegovy since January 2026 has run on one premise: same drug, no shot. For patients with needle concerns, cold-storage logistics, or privacy preferences around injections, the pill form is positioned as a seamless substitute. The administration requirement that tends to get lighter treatment in the excitement: oral semaglutide must be taken on an empty stomach, followed by 30 minutes without food or other medications, with no more than four ounces of water. The injectable weekly administration is meaningfully simpler. The 2 million prescriptions figure reflects genuine pent-up demand for a needle-free GLP-1 option. Whether real-world adherence to the pill's fasting window matches the enthusiasm of first-fill scripts is a different question — and exactly the variable the OCTANE data presenting at EASD Wednesday is designed to start answering.

What the data shows

OASIS 4 established 16.6% weight loss — the switcher data is a different study population entirely

The oral Wegovy FDA approval rested on the OASIS 4 Phase 3 trial, which showed 16.6% mean weight loss at 68 weeks versus 2.7% with placebo in adults with obesity or overweight and weight-related comorbidities. [ClinicalTrials.gov lists the OASIS trial program](https://clinicaltrials.gov/search?term=oral+semaglutide+OASIS+obesity). That is a substantial effect, and the December 2025 approval was substantive. But OASIS 4 enrolled a de novo population — patients who had never been on injectable GLP-1 therapy. The OCTANE study data at EASD characterizes a different group: people already established on injectable semaglutide or tirzepatide who voluntarily moved to the oral form. What maintained, what regressed, and over what time window — that is the evidence the commercial market needs but that the approval trial was not designed to provide. A July 2026 paper in Nature Communications added another signal: UCSD researchers found a 9% slower DunedinPACE epigenetic aging rate in HIV patients on semaglutide compared to placebo. The authors were explicit that the drug was not an anti-aging treatment. The aging narrative traveled faster than the study's population caveats.

Approved — PeptideFactCheck stance

the approved label is the anchor — everything else is a question the real world is now running

Semaglutide holds PeptideFactCheck's Approved evidence tier, and the trail is among the most documented of any compound the site covers. Ozempic, Wegovy, Rybelsus, and the newer Wegovy HD 7.2 mg approved in March 2026 each carry their own labeled indications supported by Phase 3 trial programs spanning diabetes, obesity, cardiovascular disease, kidney disease, and liver conditions. The oral Wegovy carries a separate December 2025 approval grounded specifically in the OASIS 4 data. [The official DailyMed label](https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=semaglutide) is the primary document defining what has been reviewed and for whom. Approved status means the evidence program was sufficient for a specific regulatory conclusion about specific populations. It does not mean all downstream uses and claims are validated — the anti-aging signal is from HIV patients, the cardiovascular data is from a cardiovascular disease population, and the real-world switcher experience is now being characterized for the first time. [FDA's warning about unapproved GLP-1 products](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) applies across formulations. An approved record is not the same as an approved claim for every population the internet now reaches. Source trail before certainty.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.